Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence

Chronic IL-1 treatment selects for cells that are less sensitive to cytotoxicity associated with serum starvation, loss of AR expression, and inflammatory cytokine signaling. LNCaP cells were treated with 0.5 ng/ml IL-1 alpha (in DMEM + 10% FBS) for 3 months or treated with 0.5 ng/ml IL-1 beta (in DMEM + 10% FBS) for 4 months. IL-1 is cytotoxic, so the viable, proliferating colonies that emerged after 3 months in IL-1a or 4 months in IL-1b were expanded to generate the IL-1a subline (LNas1) and the IL-1b subline (LNbs1). LNCaP, LNas1, and LNbs1 cells were plated and cultured in DMEM + 10% FBS for 7 days and RNA isolated for RNA sequencing.